目次

Table of Content

1. Introduction to TROP2 Targeting Therapy Market
1.1 Overview
1.2 TROP2 Targeting Therapeutics Mechanism
1.3 TROP2 Ideal Clinical Biomarker For Cancer

2. Global TROP2 Targeted Antibodies Clinical Trials Insight
2.1 By Company
2.2 By Country
2.3 By Patient Segment
2.4 By Phase
2.5 By Priority Status

3. Global TROP2 Antibody Market Outlook
3.1 Current Market Scenario
3.2 Future Market Opportunities

4. Unveiling TROP2 Therapeutic Frontiers Market Trend By Region
4.1 US
4.2 China
4.3 Australia
4.4 South Korea
4.5 Europe
4.6 Taiwan
4.7 Japan

5. Global TROP2 Targeting Antibodies Market By Cancer
5.1 Breast Cancer
5.2 Lung Cancer
5.3 Gastrointestinal Cancer
5.4 Urothelial Cancer
5.5 Ovarian Cancer

6. Trodelvy - First Approved TROP2 Targeting Therapy
6.1 Overview, Availability and Patent Insight
6.2 Dosage and Price Analysis
6.3 Sales Analysis (2020 - 2024)

7. Sacituzumab Tirumotecan
7.1 Overview, Availability and Patent Insight

8. Datroway
8.1 Overview, Availability and Patent Insight
8.2 Dosage and Price Analysis

9. TROP2 Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase I
9.4 Phase I/II
9.5 Phase II
9.6 Phase III

10. Marketed TROP2 Antibody Clinical Insight

11. Combination Approaches for TROP2 Antibody

12. Competitive Landscape
12.1 Aptamer Sciences
12.2 Aston Science
12.3 AstraZeneca
12.4 Beijing Biocytogen
12.5 BiOneCure Therapeutics
12.6 Biosion
12.7 Bio-Thera Solutions
12.8 Daiichi Sankyo Company
12.9 Hangzhou DAC Biotech
12.10 Innovent Biologics
12.11 LegoChem Biosciences
12.12 Merck
12.13 OBI Pharma
12.14 Peak Bio
12.15 Shanghai Henlius Biotech
12.16 Suzhou GeneQuantum Healthcare

List of Figures & Tables
Figure 1-1: History and Milestones In TROP2 Targeting Therapeutics Market
Figure 1-2: TROP2 Stimulated Effectors, Biomarker and Pathways
Figure 1-3: TROP2 Regulated Oncogenic Cell Signaling Pathways
Figure 1-4: General Mechanism of TROP2 Targeting ADC
Figure 1-5: Trodelvy - Mechanism Of Action
Figure 1-6: Frequency of TROP2 Expression by Cancer Type (%)
Figure 1-7: Role of TROP2 In Cancer
Figure 2-1: Global -TROP2 Antibodies Clinical Pipeline By Company, 2025 - 2030
Figure 2-2: Global - TROP2 Antibodies Clinical Pipeline By Country, 2025 - 2030
Figure 2-3: Global - TROP2 Antibodies Clinical Pipeline By Patient Segment, 2025 - 2030
Figure 2-4: Global - TROP2 Antibodies Clinical Pipeline By Phase, 2025 - 2030
Figure 2-5: Global - TROP2 Antibodies Clinical Pipeline By Priority Status, 2025 - 2030
Figure 3-1: Phase 3 - Key TROP2 Drugs and Companies
Figure 3-2: Global - TROP2 Targeting Therapy Market (US$ Million), 2020-2024
Figure 3-3: Global - TROP2 Antibody Market (US$ Million), Q1-Q4’2024
Figure 3-4: Global - TROP2 Antibody Market By Region (US$ Million), 2024
Figure 3-5: Global - TROP2 Antibody Market By Region (%), 2024
Figure 3-6: Future TROP2 Market
Figure 3-7: Global - TROP2 Antibodies Market (US$ Million), 2025 - 2030
Figure 4-1: China TROP2 - Key Players and Drugs
Figure 4-2: FDA018-ADC Phase III Study (NCT06519370) - Initiation and Completion Year
Figure 4-3: South Korea - Key TROP2 Companies
Figure 4-4: OBI Pharma TROP2 Therapy Pipeline
Figure 5-1: Breast Cancer - Estimated and Projected Cases, 2022 and 2030
Figure 5-2: TROPION-Breast01 (NCT05104866) Phase 3 Study - Initiation and Completion Year
Figure 5-3: ESG401-101 (NCT04892342) Phase 1a/1b Study - Initiation and Completion Year
Figure 5-4: ESG401-301 (NCT06383767) Phase 3 Study - Initiation and Completion Year
Figure 5-5: ESG401-302 (NCT06732323) Phase 3 Study - Initiation and Completion Year
Figure 5-6: Lung Cancer - Estimated and Projected Cases, 2022 and 2030
Figure 5-7: EVOKE-01 (NCT05609968) Phase 3 Study - Initiation and Completion Year
Figure 5-8: EVOKE-03 (NCT05609968) Phase 3 Study - Initiation and Completion Year
Figure 5-9: EVOKE-02 (NCT05186974) Phase 2 Study - Initiation and Completion Year
Figure 5-10: Gastrointestinal Cancer - Estimated and Projected Cases, 2022 and 2030
Figure 5-11: KL264-01 Phase 1/2 Study - Initiation and Completion Year
Figure 5-12: MK-3475-06C (NCT06469944) Phase 1/2 Study - Initiation and Completion Year
Figure 5-13: MK-2870-015 (NCT06356311) Phase 3 Study - Initiation and Completion Year
Figure 5-14: OBI-992-001 (NCT06480240) Phase 1/2 Study - Initiation and Completion Year
Figure 5-15: MT-302 Phase I Study (NCT05969041) - Initiation and Completion Year
Figure 5-16: Urothelial Cancer - Estimated and Projected Cases, 2022 and 2030
Figure 5-17: Urothelial Cancer - Estimated and Projected Cases, 2022 and 2030
Figure 5-18: BNT-325 (NCT05438329) Phase 1/2 Study - Initiation and Completion Year
Figure 5-19: TROPION-PanTumor03 (NCT05489211) Phase 2 Study - Initiation and Completion Year
Figure 6-1: Trodelvy - Patent Expiration Year By Region
Figure 6-2: Trodelvy - Approval Year By Region
Figure 6-3: Trodelvy - FDA Orphan Designation Year By Indication
Figure 6-4: US - Price Of 180mg Vial Of Trodelvy Intravenous Powder (US$), February’2025
Figure 6-5: EU - Price Of 180mg and 200mg Vials Of Trodelvy Intravenous Powder (US$), February’2025
Figure 6-6: Global - Trodelvy Sales (US$ Million), 2020-2024
Figure 6-7: Global - Trodelvy Sales (US$ Million), Q1-Q4’2024
Figure 6-8: Regional -Trodelvy Sales by Region (US$ Million), 2024
Figure 6-9: Trodelvy Sales By Region (%),2024
Figure 6-10: US -Trodelvy Sales (US$ Million), 2021-2024
Figure 6-11: US -Trodelvy Sales (US$ Million), Q1-Q4’2024
Figure 6-12: Europe - Trodelvy Sales (US$ Million), 2021-2024
Figure 6-13: Europe - Trodelvy Sales (US$ Million), Q1-Q4’2024
Figure 6-14: ROW - Trodelvy Sales (US$ Million), 2021-2024
Figure 6-15: ROW - Trodelvy Sales (US$ Million), Q1-Q4’2024
Figure 11-1: TROP2 Antibodies Combinations
Table 4-1: US - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-2: China - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-3: Preclinical TROP2 Candidates Development In China
Table 4-4: Australia - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-5: South Korea - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-6: Europe - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-7: Taiwan - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 4-8: Japan - Ongoing Clinical Trials For TROP2 Targeting Therapies
Table 5-1: Breast Cancer - Approved TROP2 Targeted Therapies
Table 5-2: Breast Cancer - Some TROP2 Targeted Candidates In Development
Table 5-3: Lung Cancer - TROP2 ADCs Under Review
Table 5-4: Lung Cancer - Some TROP2 Targeted Candidates In Development
Table 5-5: Gastric Cancer - Some TROP2 Targeted Candidates In Development
Table 5-6: Urothelial Cancer -Key TROP2 Targeted Candidates In Development
Table 5-7: Urothelial Cancer - Key TROP2 Targeted Candidates In Development
Table 6-1: Trodelvy - Dose Modifications For Adverse Reactions
Table 8-1: Datroway - Premedication and Concomitant Medications
Table 8-2: Datroway - Recommended Dosage Reductions For Adverse Reactions
Table 8-3: Datroway - Recommended Dosage Modifications
Table 11-1: TROP2 Targeting Therapy Combination In Development